{kanada_flagge}Going forward, one of the largest government hospital groups in India will use Predictmedix Inc’s (CSE: PMED; OTCQB: PMEDF; FRA:3QP) AI-based health screening. Predictmedix announced today that India’s MGM Healthcare Group has signed a three-year contract totaling CAD 500,000. MGM will install five Predictmedix Safe Entry Stations to test patients for infectious diseases at the point of entry and segregate them if necessary. The order was preceded by a 400-patient clinical trial conducted by MGM Healthcare to determine the effectiveness of Predictmedix’s AI-powered screening technology.
{kanada_flagge}Going forward, one of the largest government hospital groups in India will use Predictmedix Inc’s (CSE: PMED; OTCQB: PMEDF; FRA:3QP) AI-based health screening. Predictmedix announced today that India’s MGM Healthcare Group has signed a three-year contract totaling CAD 500,000. MGM will install five Predictmedix Safe Entry Stations to test patients for infectious diseases at the point of entry and segregate them if necessary. The order was preceded by a 400-patient clinical trial conducted by MGM Healthcare to determine the effectiveness of Predictmedix’s AI-powered screening technology.
Safe Entry is a fully patented system for rapid and autonomous screening of individuals’ key vital signs. Similar to an airport security scanner, it is a walk-in system where a person stands in front of the device for 2 to 3 seconds while multispectral imaging cameras capture the necessary information. Parameters such as temperature, heart rate and respiration rate are recorded non-invasively and AI/ML algorithms calculate a result. Vital signs provide important information about a person’s condition, whether it’s health complications, the flu, fatigue, or even disability. Safe Entry never collects or stores personal identity information.
New technology eases the burden on staff
MGM Healthcare expects the AI-powered technology to ease the burden on staff. By quickly analyzing a person’s vital signs, Safe Entry can reduce patient wait and processing times, allowing healthcare providers to focus on providing timely care to patients who need it most. This non-invasive method of taking vital signs is more convenient for patients, which can lead to an overall better patient experience. By improving patient care and streamlining workflow, Safe Entry offers a comprehensive solution for healthcare facilities looking to expand their capabilities.
Dr. Rahul Kushwah, COO of Predictmedix commented, “There are 69,000 hospitals in India alone. South Asia and ASEAN countries represent a great opportunity for Predictmedix to improve healthcare in regions with large populations. Our technology has shown promising results in a recently completed clinical trial involving 1600 people at an Indonesian university. We strongly believe that our innovative technology can play a critical role in improving healthcare delivery and easing the burden on healthcare systems.”
Summary: The order from one of the largest hospital groups in India is a milestone for Predictmedix. If the Safe Entry System proves itself in practice, the order from MGM could open the door to many more orders in India, as well as throughout the Asian region. It is no coincidence that these regions, of all places, are receptive to fast, innovative solutions in health screening or triage. On the one hand, the rapidly growing population demands access to medical care in hospitals, while on the other hand, human resources are limited. We may well see the AI-based innovation of non-invasive health screening catch on first in the Asian region, and then later be accepted in Western industrialized countries. There are bottlenecks in personnel here as well as there, but the forces of inertia and skepticism toward innovations are certainly greater in Western industrialized countries than in Asia.
Disclaimer: GOLDINVEST Consulting GmbH publishes comments, analyses and news on https://goldinvest.de. These contents serve exclusively the information of the readers and do not represent a call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the discussed stock(s) or a solicitation to buy or sell securities. It is expressly not a financial analysis, but a promotional/journalistic text. Readers who make investment decisions or execute transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, because our information refers only to the company, but not to the investment decision of the reader.
The acquisition of securities is associated with high risks, which can lead to a total loss of the invested capital. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the content guarantee for topicality, correctness, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.
Pursuant to §34b WpHG and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH and/or partners, principals or employees of GOLDINVEST Consulting GmbH hold shares in Predictmedix and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares of the company at any time. Furthermore, GOLDINVEST Consulting GmbH is remunerated by Predictmedix for reporting on the company. This is another clear conflict of interest.
